NOBLESVILLE, Ind.–(BUSINESS WIRE)–Nexxt Spine, LLC, a medical device company focused on designing, manufacturing and distributing innovative spinal solutions, today announced the full market release of the INERTIA CORTI-FIXX™ Cortical-Cancellous Pedicle Screw System. Corti-Fixx screws are designed to achieve greater cortical bone purchase with a smaller midline incision when utilized in a medial to lateral pedicle approach known as the Cortical Bone Trajectory (CBT).

Corti-Fixx implants and instruments are built upon the Inertia Pedicle Screw System’s foundation and offer an alternative to traditional pedicle screw fixation. The unique dual to quad lead threads double the number of screw-to-bone contact points within the pedicle thereby increasing resistance to pull out.

Andy Elsbury, President of Nexxt Spine, stated, “Trends within the spine market call for less invasive procedures that are simple, reliable and reproducible. The Corti-Fixx screw further differentiates the Inertia Pedicle Screw System and provides multiple solutions for fixation in diminished bone quality through an open or MIS approach.”

About Nexxt Spine

Nexxt Spine, LLC is a privately held medical device manufacturer dedicated to increasing procedural efficiency and patient outcomes through development of innovative products, manufactured on the most technologically advanced platforms, and utilizing irreproachable quality standards to treat painful and debilitating spinal pathologies.

Additional information can be found at www.nexxtspine.com.

MEQUON, Wis.–(BUSINESS WIRE)–Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it has achieved record sales revenue for the first quarter of 2017. Additionally, the company recently exceeded 1,000 implantations of its Endoskeleton^® titanium interbody fusion devices featuring nanoLOCK^® surface technology since its launch in the fourth quarter of 2016. nanoLOCK^® is the company’s next-generation surface technology featuring enhanced micro and nano-scaled architecture, proven to significantly improve the osteogenic response it creates.¹ Titan Spine will be showcasing nanoLOCK^® at booth #2249 during the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, taking place April 22-26 in Los Angeles.

The company reports the following:

• Record quarterly sales for Q1 2017 that are significantly greater than prior year
• nanoLOCK^® has been utilized to date by 74 surgeons in 52 hospitals across 26 states
• nanoLOCK^® sales volume has increased by 270% since December 2016

Ted Bird, Chief Commercial Officer of Titan Spine, commented, “Achieving record sales growth in the first quarter this year speaks to the accelerating demand for our surface-enhanced titanium interbody devices and an increasing appreciation of the importance of our proprietary nano-architecture in its ability to drive rapid osteogenesis. The attainment of the 1,000-unit threshold of our nanoLOCK^®device in just six months of its commercial availability underscores the market demand for devices that benefit patients in the early post-op timeframe as spine surgeons are now under the microscope for improved early results more than ever before. Our rapid nanoLOCK^®adoption has certainly been aided by its sole access to the CMS new technology ICD-10 code for nanotextured interbody fusion devices, which has placed nanoLOCK^® in a category all its own and has resulted in a dramatic increase in the number of hospitals and surgeons that have access to it. We could not be more pleased with our sales results to date and the continued successful launch of nanoLOCK^®.”

Steve Cichy, Executive Vice President of Sales of Titan Spine, added, “Our Q1 achievements reflect the growing demand from our current surgeon base plus new relationships we have made with surgeon adopters that are beginning to embrace the benefits of nanotechnology for their patients. As a result, we have significantly invested in our field sales management team by tripling the number of Area Vice Presidents and Regional Managers we employ in just under a year. We are uniquely positioned to continue to take market share throughout the rest of 2017 and beyond.”

Titan Spine offers a full line of Endoskeleton^® devices that feature Titan Spine’s proprietary nanoLOCK^® surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and nano levels (MMN™). This unique combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins (BMPs), downregulating inflammatory factors, and creating the potential for a faster and more robust fusion.^2,3,4 All Endoskeleton^® devices are covered by the company’s risk share warranty.

About Titan Spine

Titan Spine, LLC is a surface technology company focused on the design and manufacture of interbody fusion devices for the spine. The company is committed to advancing the science of surface engineering to enhance the treatment of various pathologies of the spine that require fusion. Titan Spine, located in Mequon, Wisconsin and Laichingen, Germany, markets a full line of Endoskeleton^® interbody devices featuring its proprietary textured surface in the U.S. and portions of Europe through its sales force and a network of independent distributors. To learn more, visit www.titanspine.com.

¹ Olivares-Navarrete, R., Hyzy S.L., Gittens, R.A., Berg, M.E., Schneider, J.M., Hotchkiss, K., Schwartz, Z., Boyan, B. D. Osteoblast lineage cells can discriminate microscale topographic features on titanium-aluminum-vanadium surfaces. Ann Biomed Eng. 2014 Dec; 42 (12): 2551-61.

² Olivares-Navarrete, R., Hyzy, S.L., Slosar, P.J., Schneider, J.M., Schwartz, Z., and Boyan, B.D. (2015). Implant materials generate different peri-implant inflammatory factors: PEEK promotes fibrosis and micro-textured titanium promotes osteogenic factors. Spine, Volume 40, Issue 6, 399–404.

³ Olivares-Navarrete, R., Gittens, R.A., Schneider, J.M., Hyzy, S.L., Haithcock, D.A., Ullrich, P.F., Schwartz, Z., Boyan, B.D. (2012). Osteoblasts exhibit a more differentiated phenotype and increased bone morphogenetic production on titanium alloy substrates than poly-ether-ether-ketone. The Spine Journal, 12, 265-272.

⁴ Olivares-Navarrete, R., Hyzy, S.L., Gittens, R.A., Schneider, J.M., Haithcock, D.A., Ullrich, P.F., Slosar, P. J., Schwartz, Z., Boyan, B.D. (2013). Rough titanium alloys regulate osteoblast production of angiogenic factors. The Spine Journal, 13, 1563-1570.

ALLENDALE, N.J.–(BUSINESS WIRE)–Stryker’s Spine division will exhibit its comprehensive suite of spinal products at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, April 22–26, 2017, at the Los Angeles Convention Center (booth No. 1301). This exhibition includes a number of advanced spinal products and technologies that Stryker’s Spine division has introduced in the past year. The company also will offer a Lunch-and-Learn educational program for AANS members attending the meeting.

“This is an exciting time, both for the field of spinal surgery and for Stryker’s Spine division,” said Bradley Paddock, President of the company’s Spine division. “Our expanding portfolio of spinal procedural innovations and differentiated technologies demonstrates our commitment to bringing state-of-the-art products to physicians and their patients. We will continue to increase and strengthen our leadership position in this segment and are thrilled to showcase our latest technology advances at the AANS conference.”

Stryker’s Spine division’s products offer advancements for both traditional and minimally invasive surgical techniques. Recently introduced technologies that will be highlighted at the meeting include:

• The Tritanium Posterior Lumbar (PL) Cage, a 3D-printed interbody fusion device designed to aid in lumbar spinal fixation for patients with degenerative disc disease, including up to Grade 1 spondylolisthesis, and degenerative scoliosis. It is manufactured using Stryker’s proprietary Tritanium Technology, which allows for the creation of porous structures that are designed to mimic cancellous bone in pore size, level of porosity, and interconnectivity of the pores.¹ The cage is now offered in a variety of new sizes, which were introduced at the 2017 AAOS conference in March.
• Aero-C Cervical Stability System (Aero-C), the only StraightForward anterior cervical discectomy and fusion (ACDF) device that offers uniform compression across the interbody space.² Using Aerofoil™ Compression Technology, Aero-C is designed to pull the vertebral bodies toward the implant as it is inserted, creating compressive forces at the implant-to-endplate interface.²
• Xia CT (Xia 4.5 Cortical Trajectory), which includes implants and instruments used in less invasive LITe LIF posterior lumbar interbody fusion procedures for patients with degenerative disc disease, spondylolisthesis, and trauma. The cortical trajectory procedure facilitates a smaller midline incision to help achieve decompression, fixation, and fusion.³ It also is intended to be more muscle sparing than standard open procedures that require lateral dissection, and its reduced incision may allow for more efficient exposure and closure time.³
• The LITe BIO Delivery System, a hand-held device used to facilitate delivery of bone graft material to spinal surgery sites, simplifies graft delivery, accommodates a surgeon’s preferred graft materials,⁴ and allows for direct visualization of graft placement. The unique design of the LITe BIO Delivery System provides surgeons with a single-handed method to deliver any type of autograft, allograft, or synthetic bone graft material without obstructing visibility. The innovative delivery tool provides tactile, visual, and audible confirmation of bone graft delivery, and the mallet-free system eliminates the impaction of bone graft.

Stryker’s Spine division will host the Lunch-and-Learn seminar, “Tritanium: A Novel Highly Porous Titanium Alloy for Interbody Fusion Procedures,” Monday, April 24 from 1:10–1:55 p.m. The seminar will be presented by Matthew J. McGirt, M.D., from the Department of Neurosurgery at the University of North Carolina.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information at www.stryker.com.

References

1. Karageorgiou V, Kaplan D. (2005) Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials, 26, 5474-5491.
2. PROJ0000050417 Aero-C Anchor Induced Compression Testing Design Iteration Memo
3. Lee GW, Son JH, Ahn MW, Kim HJ, Yeom JS. (2015) The comparison of pedicle screw and cortical screw in posterior lumbar interbody fusion: a prospective randomized noninferiority trial. The Spine Journal 15, 1519-1526.
4. FDA Cleared Indications for Use: The LITe BIO Delivery System is intended to deliver autograft, allograft or synthetic bone graft materials to all orthopaedic surgical sites.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Aero, Aerofoil, LITe, StraightForward, Stryker, Tritanium, and Xia. All other trademarks are trademarks of their respective owners or holders.

Content ID TRITA-PR-7_13958